Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Asymmetric Synthesis of Akt Kinase Inhibitor Ipatasertib.

Han C, Savage S, Al-Sayah M, Yajima H, Remarchuk T, Reents R, Wirz B, Iding H, Bachmann S, Fantasia SM, Scalone M, Hell A, Hidber P, Gosselin F.

Org Lett. 2017 Sep 15;19(18):4806-4809. doi: 10.1021/acs.orglett.7b02228. Epub 2017 Aug 31.

PMID:
28858516
2.

Extended Catalytic Scope of a Well-Known Enzyme: Asymmetric Reduction of Iminium Substrates by Glucose Dehydrogenase.

Roth S, Präg A, Wechsler C, Marolt M, Ferlaino S, Lüdeke S, Sandon N, Wetzl D, Iding H, Wirz B, Müller M.

Chembiochem. 2017 Sep 5;18(17):1703-1706. doi: 10.1002/cbic.201700261. Epub 2017 Jul 19.

PMID:
28722796
3.

Amine Transaminase Engineering for Spatially Bulky Substrate Acceptance.

Weiß MS, Pavlidis IV, Spurr P, Hanlon SP, Wirz B, Iding H, Bornscheuer UT.

Chembiochem. 2017 Jun 1;18(11):1022-1026. doi: 10.1002/cbic.201700033. Epub 2017 Apr 27.

PMID:
28334484
4.

Protein-engineering of an amine transaminase for the stereoselective synthesis of a pharmaceutically relevant bicyclic amine.

Weiß MS, Pavlidis IV, Spurr P, Hanlon SP, Wirz B, Iding H, Bornscheuer UT.

Org Biomol Chem. 2016 Nov 2;14(43):10249-10254.

PMID:
27739550
5.

Identification of (S)-selective transaminases for the asymmetric synthesis of bulky chiral amines.

Pavlidis IV, Weiß MS, Genz M, Spurr P, Hanlon SP, Wirz B, Iding H, Bornscheuer UT.

Nat Chem. 2016 Nov;8(11):1076-1082. doi: 10.1038/nchem.2578. Epub 2016 Jul 18.

PMID:
27768108
6.

Human xanthine oxidase recombinant in E. coli: A whole cell catalyst for preparative drug metabolite synthesis.

Ferreira Antunes M, Eggimann FK, Kittelmann M, Lütz S, Hanlon SP, Wirz B, Bachler T, Winkler M.

J Biotechnol. 2016 Oct 10;235:3-10. doi: 10.1016/j.jbiotec.2016.03.045. Epub 2016 Mar 25. Review.

PMID:
27021957
7.

Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis.

Geier M, Bachler T, Hanlon SP, Eggimann FK, Kittelmann M, Weber H, Lütz S, Wirz B, Winkler M.

Microb Cell Fact. 2015 Jun 12;14:82. doi: 10.1186/s12934-015-0262-0.

8.

Expanding the Imine Reductase Toolbox by Exploring the Bacterial Protein-Sequence Space.

Wetzl D, Berrera M, Sandon N, Fishlock D, Ebeling M, Müller M, Hanlon S, Wirz B, Iding H.

Chembiochem. 2015 Aug 17;16(12):1749-56. doi: 10.1002/cbic.201500218. Epub 2015 Jul 2.

PMID:
26044455
9.

Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds.

Hilpert H, Mauser H, Humm R, Anselm L, Kuehne H, Hartmann G, Gruener S, Banner DW, Benz J, Gsell B, Kuglstatter A, Stihle M, Thoma R, Sanchez RA, Iding H, Wirz B, Haap W.

J Med Chem. 2013 Dec 12;56(23):9789-801. doi: 10.1021/jm401528k. Epub 2013 Nov 22.

PMID:
24224654
10.

Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro.

Gschwind HP, Glaenzel U, Waldmeier F, Wirz B, Sabia HD, Picard F, Weiss HM, Choi L, Swart PJ, Vasudevan A, Azria M.

Eur J Pharm Sci. 2012 Aug 30;47(1):44-55. doi: 10.1016/j.ejps.2012.04.023. Epub 2012 May 8.

PMID:
22579664
11.

Expression of recombinant human flavin monooxygenase and moclobemide-N-oxide synthesis on multi-mg scale.

Hanlon SP, Camattari A, Abad S, Glieder A, Kittelmann M, Lütz S, Wirz B, Winkler M.

Chem Commun (Camb). 2012 Jun 18;48(48):6001-3. doi: 10.1039/c2cc17878h. Epub 2012 May 10.

PMID:
22576266
12.

Swiss Industrial Biocatalysis Consortium (SIBC).

Wirz B, Kittelmann M, Meyer HP, Wohlgemuth R.

Chimia (Aarau). 2010;64(11):780-1.

PMID:
21197839
13.

Inflammatory responses predict long-term mortality risk in community-acquired pneumonia.

Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P.

Eur Respir J. 2011 Jun;37(6):1439-46. doi: 10.1183/09031936.00121510. Epub 2010 Nov 11.

14.

New, efficient synthesis of oseltamivir phosphate (Tamiflu) via enzymatic desymmetrization of a meso-1,3-cyclohexanedicarboxylic acid diester.

Zutter U, Iding H, Spurr P, Wirz B.

J Org Chem. 2008 Jul 4;73(13):4895-902. doi: 10.1021/jo800264d. Epub 2008 Jun 3.

PMID:
18517254
15.

ADME investigations of unnatural peptides: distribution of a 14C-labeled beta 3-octaarginine in rats.

Weiss HM, Wirz B, Schweitzer A, Amstutz R, Rodriguez Perez MI, Andres H, Metz Y, Gardiner J, Seebach D.

Chem Biodivers. 2007 Jul;4(7):1413-37.

PMID:
17638323
16.

Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.

Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ, End P, Vaidyanathan S.

Drug Metab Dispos. 2007 Aug;35(8):1418-28. Epub 2007 May 17.

PMID:
17510248
17.

Pharmacokinetic investigation of a 14C-labelled beta 3/alpha tetrapeptide in rats.

Wiegand H, Wirz B, Schweitzer A, Gross G, Perez MI, Andres H, Kimmerlin T, Rueping M, Seebach D.

Chem Biodivers. 2004 Nov;1(11):1812-28.

PMID:
17191818
18.

The outstanding metabolic stability of a 14C-labeled beta-nonapeptide in rats--in vitro and in vivo pharmacokinetic studies.

Wiegand H, Wirz B, Schweitzer A, Camenisch GP, Rodriguez Perez MI, Gross G, Woessner R, Voges R, Arvidsson PI, Frackenpohl J, Seebach D.

Biopharm Drug Dispos. 2002 Sep;23(6):251-62.

PMID:
12214326
19.

4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.

Buchdunger E, Mett H, Trinks U, Regenass U, Müller M, Meyer T, Beilstein P, Wirz B, Schneider P, Traxler P, et al.

Clin Cancer Res. 1995 Aug;1(8):813-21.

20.

Large scale preparation of chiral building blocks for the P3 site of renin inhibitors.

Doswald S, Estermann H, Kupfer E, Stadler H, Walther W, Weisbrod T, Wirz B, Wostl W.

Bioorg Med Chem. 1994 Jun;2(6):403-10.

PMID:
8000860
21.

Detection of hog cholera virus and differentiation from other pestiviruses by polymerase chain reaction.

Wirz B, Tratschin JD, Müller HK, Mitchell DB.

J Clin Microbiol. 1993 May;31(5):1148-54.

Supplemental Content

Support Center